Navigating the Operational Challenges of Treatment with Bispecific Antibodies - [Podcast] Ep 148

Advancements in clinical data and research have shown the immunotherapeutic potential of bispecific antibodies as treatment for hematologic cancers and solid tumors. In this episode, CANCER BUZZ speaks with Aaron Cumpston, PharmD, pharmacy clinical specialist in hematologic malignancies and bone marrow transplant and Christine Barrett, PharmD, BCOP, medical oncology clinical pharmacy specialist at WVU Cancer Institute who discuss the challenges of care coordination and therapy and share operational best practices for the delivery of bispecific antibodies in the community setting.  

“I think we’re finding these drugs [bispecific T-cell engagers (BiTE) therapies] to be highly effective and having high response rates and also very durable response rates in very refractory patients.”—Aaron Cumpston, PharmD, BCOP

“I know that in community practice it can be really difficult, but there is a network of institutions out there that have taken on administering these BiTE therapies and have a lot of experience that can be very helpful for those in community practice.” —Christine Barrett, PharmD, BCOP

Guests:

Aaron Cumpston, PharmD, BCOP 

Pharmacy Clinical Specialist – Hematologic Malignancy, Transplant, and Cellular Therapy

WVU Medicine 

WVU Cancer Institute - Mary Babb Randolph Cancer Center 

Morgantown, WV 

Christine Barrett, PharmD, BCOP 

Medical Oncology Clinical Pharmacy Specialist 

WVU Medicine 

WVU Cancer Institute - Mary Babb Randolph Cancer Center 

Morgantown, WV 

This episode was developed in connection with the ACCC education program Sharing Operational Insights for the Delivery of Bispecific Antibodies in Solid Tumor and is supported by Amgen.

Resources:

• Expanding Access to Cellular and Bispecific Therapies – Considerations and Recommendations by ACCC and SITC
• Sharing Operational Insights for the Delivery of Bispecific Antibodies in Solid Tumor
• Best Practices in Expanding Access to Bispecific Antibodies and Adverse Event Management